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Current systemic treatment options for patients with hep-
atocellular carcinoma (HCC) are limited to sorafenib. With the
recent FDA approval of the second PD1-PD-L1 pathway inhibitor,
immunotherapy has gained even more interest as a potential
novel treatment option for patients with HCC. This is due not only
because of the failure of other treatment approaches in the past,
but also because immunological mechanisms have been shown
to play an important role during tumor development, growth,
and treatment. Here we present a review of immunological
mechanisms in the liver relevant for tumor progression and treat-
ment. We summarize our current knowledge on immune activat-
ing and immune suppressing mechanisms during tumor
initiation, development, and treatment. We try to explain the
paradox of how inﬂammatory responses in a setting of chronic
infection promote tumor development, while the primary aim
of immunotherapy is to activate immunity. Finally we summarize
recent advances in addition to providing an outlook for the
immunotherapy of HCC.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver. Open access under CC BY-NC-ND license.Introduction
Primary liver cancer, a disease of etiologic and geographic diver-
sity, is now the second most common cause of cancer related
death worldwide, with hepatocellular carcinoma (HCC) account-
ing for the majority of these cases [1]. Globally, the number of
deaths from HCC is close to the number of new patients diag-
nosed. The majority of all HCC incidence is a consequence of
chronic viral infection with hepatitis B (HBV) and C (HCV) [2]
and develops in the setting of persistent immune modulation
by chronic viral inﬂammation. The HBV vaccine, which is the ﬁrst
adaptive immunity intervention to prevent cancer development,Journal of Hepatology 20
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E-mail address: tim.greten@nih.gov (T.F. Greten).was introduced worldwide in the 1980s. Since that time, a
decreased incidence of HCC has been reported in Asia, where
HBV-associated HCC is endemic [3]. In recent years, diabetes
and obesity (and consecutive non-alcoholic steatohepatitis
(NASH)) have been receiving growing attention as risk factors
for tumor development in the US [4]. Surgery and local ablative
therapies remain the only curative treatment option while
intra-arterial treatments (transarterial chemoembolization –
TACE- and selective intra-arterial radiotherapy-SIRT-) and sys-
temic chemotherapy are used in the palliative setting in patients
with more advanced disease [5]. Currently, the only FDA
approved systemic treatment for HCC is sorafenib, a multikinase
inhibitor. Sorafenib was established as the standard of care in
advanced HCC after a phase III randomized, placebo controlled
clinical trial showed a small improvement in overall survival
(OS) from 7.9 months to 10.7 months [6]. Thus there is a clear
and urgent need for new therapies for this deadly disease.
Chronic hepatic inﬂammatory responses are the number one
risk factor for liver tumor development. At the same time,
immune based approaches aimed at enhancing tumor-speciﬁc
immune responses are currently under investigation as therapeu-
tic strategies in HCC cancer research. A better understanding of
how the immune system promotes tumor growth will hopefully
lead to the development of more effective treatment options and
will be the focus of this review (Fig. 1). In addition we will discuss
currently ongoing and recent clinical trials aiming to enhance
anti-tumor immunity either by inducing antigen-speciﬁc T cells
or by blocking immune inhibitory mechanisms.
Tolerance inducing mechanisms in the liver
Under physiological conditions, the liver has to perform multiple
tasks, including the uptake of blood borne pathogens, the excre-
tion of toxic waste substances, and the ﬁltration of environmental
or bacterial agents from the gastrointestinal tract. These func-
tions result in enormous antigen exposure to the liver [7,8]. To
prevent organ autoimmune damage from ongoing immune stim-
ulation by a myriad of antigens, liver evolution resulted in the
development of intrinsic liver tolerogenic mechanisms in the
innate and adaptive immune response [8–12] (Fig. 2).
Under physiological conditions, cells of the innate immune
system such as Kupffer cells, which are resident macrophages
of the liver, release interleukin (IL)-10 [10] and, consequently,
inhibit immune responses. Furthermore, constitutive release of
another active inhibitory cytokine, transforming growth factor15 vol. 62 j 1420–1429
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Fig. 2. Under physiological conditions the liver has the capacity to induce
tolerance against antigens delivered from the intestine. The identiﬁed immune
responses promoting liver tolerance to antigens include constitutive inhibitory
cytokine release (interleukin 10 (IL-10) by Kupffer cells (KC) and tumor growth
factor beta (TGF-b) by KC or liver sinusoidal endothelial cells (LSEC)), and
upregulation of immune checkpoints (programmed death-ligand 1 or 2 (PD-L1 or
PD-L2) on hepatocytes (HC), hepatic stellate cells (HSC), KC, LSEC and intrahepatic
leucocytes (LC), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on T
regulatory cells (Treg)). All of these immune responses protect the liver from
autoimmune damage by blocking activation of effector T cells in the liver
microenvironment. While liver immune tolerance is beneﬁcial in case of harmless
antigens in cancer-free liver, it may be detrimental with respect to HCC antigen
immune escape in cancer-bearing host.
Hepatocellular
carcinoma
Liver tolerance
Chronic inflammation
dependent immune
suppression
Tumor induced
immunosuppression
Tumor
progression
Immune-targeted
therapy
Antitumor
immune response
Tumor
elimination
+
+
Fig. 1. The counteracting forces regulate the balance between tumor
progression and tumor elimination. The forces mediating tumor progression
include liver tolerance to antigens, immunosuppression of chronic inﬂammation
and HCC dependent immune tolerance. On the opposite side of the equilibrium is
anti-tumor immune response, which can be enhanced by immunotherapy such as
immune checkpoint blockade.
JOURNAL OF HEPATOLOGY(TGF)-b, by endothelial liver cells and Kupffer cells has been iden-
tiﬁed [13] as a contributor to local immunosuppression. Although
liver sinusoidal endothelial cells (LSECs) can promote differentia-
tion of T cells into memory-like T cells, which give rise to effector
T cells after reactivation by antigen presenting cells (APCs) [14]
and induces a rapid generation of cytotoxic T cells [15], tolero-
genic liver priming by endotoxins leads to defective antigen pro-
cessing by LSECs, diminishing antigen-speciﬁc immune
surveillance [11]. Moreover, a decrease in surface expression of
immune co-stimulatory molecules, B7-1 (also known as CD80)
and B7-2 (a.k.a. CD86) [11], on LSECs limits the ability of these
APCs to activate CD4+ T cells, further decreasing adaptive
immune system surveillance in liver tissues.
The B7-1 and B7-2 molecules are expressed on various types
of APCs and are essential components of the B7-CD28/CTLA-4
immune checkpoint pathways. Interactions of B7-1 and B7-2
transmit co-stimulatory signals to antigen-primed T cells when
they are ligated with the CD28 receptor on T cells or co-inhibitory
signals when they interact with cytotoxic T-lymphocyte-associ-
ated protein 4 (CTLA-4), the inhibitory checkpoint receptor on T
cells, therefore enhancing or downregulating T cell activation.
With respect to the immunosuppressive role of CTLA-4 in the
liver, CTLA-4 expression by Foxp3+CD25+CD4+ T regulatory cells
(Tregs) has been linked to the induction of host immune toler-
ance after liver transplantation [16] and, thus represents a poten-
tial organ-speciﬁc mechanism to regulate immune activation. In
addition to the B7-CD28/CTLA-4 pathway, another immune
checkpoint pathway, PD-L1/PD-L2/PD-1 (programmed death-
ligand 1 or 2/programmed cell death 1 receptor), inhibits
immune activation in the liver [17–21]. PD-L1, expressed on hep-
atocytes [17], hepatic stellate cells (HSCs) [18], LSECs [19], and
Kupffer cells [20], contributes to mechanisms of liver immune
tolerance via induction of T cell apoptosis [17,18,21] or T cell dys-
function [19]. Furthermore, the physiologic expression of PD-L1
as well as PD-L2 and PD-1 can be increased in chronically
inﬂamed livers [20]. All of these tolerogenic responses can be
protective with respect to harmless antigens, yet detrimental in
the case of immune tolerance to tumor-associated antigens
(TAAs) and HCC progression.Journal of Hepatology 2015Immunosuppression of chronic inﬂammation
Chronic inﬂammation, characterized by the continued expression
of different cytokines [22,23] and recruitment of immune cells
[20,24,25] to the liver, contributes to HCC carcinogenesis and dis-
ease progression by enhancing immune suppression and thus
allowing the growth of cancer cells [25,26]. The inhibition of anti-
gen-speciﬁc immune surveillance in the chronic inﬂammatory
state is mediated by changes in expression of immune check-
points [23,27–29], alterations in function of dendritic cells
(DCs) [30–32], increases in the frequency of Tregs [25,33], and
release of cytokines with immune suppressive functions such as
IL-10 and TGF-b [23,33,34].
In recent years, immune inhibitory checkpoints have been
increasingly recognized as important players in immunosuppres-
sion of chronic inﬂammation. In chronic viral and autoimmune
hepatitis, upregulation of PD-1 expression on – intrahepatic lym-
phocytes and its ligands PD-L1 (a.k.a. B7-H1) and PD-L2 (a.k.a.
B7-H2), on Kupffer cells, LSECs, and leukocytes – have been posi-
tively correlated with the degree of liver inﬂammation [20].
Furthermore, the increased frequency of circulating CD8+ T cells
expressing PD-1 has been associated with progression of HBV-re-
lated cirrhosis to HCC [35]. In addition to the PD-1 [28,29,36]
upregulation, other negative T cell regulatory checkpoint recep-
tors such as CTLA-4 [29] and T cell immunoglobulin domain
and mucin domain-3 (Tim-3) [27,37], have been linked to
reduced T cell effector function in chronic viral hepatitis.
Collectively, these data suggest that immune inhibitory check-
points contribute to immunosuppression in the chronic inﬂam-
matory state, allowing HCC progression.
Interestingly, studies of patients with chronic HCV infection
showed that blocking PD-1/PD-L1 or B7-CD28/CTLA-4 signaling
restores the capacity for expansion and function of circulatingvol. 62 j 1420–1429 1421
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HCV-speciﬁc CD8+ T cells, but not for intrahepatic HCV-speciﬁc
CD8+ T cells [29,36]. The refractoriness of intrahepatic CD8+ T
cells to PD-1/PD-L1 blockage can be explained by Treg-mediated
immunosuppression, upregulation of CTLA-4 in HCV-speciﬁc
hepatic CD8+ PD-1high T cells [25] and reduced expression of
co-stimulatory molecules CD28 and CD127 (IL-7R alpha) by these
cells [29,36]. The exhaustion of intrahepatic CD8+ T cells has been
reversed by using combined PD-1 and CTLA-4 inhibition [29].
Therefore, this ﬁnding suggests that a combination of immune
targeting treatments might be necessary for restoration of anti-
gen-speciﬁc CD8+ T cell functions in chronically inﬂamed livers.
HCC immune tolerance
In tumor-bearing hosts, the strategies promoting tolerance to
tumor antigens include a decrease in recognition of malignant
cells and suppression of immune system function in the tumor
microenvironment [38], both of which can lead to cancer pro-
gression. Although the pathways involved in cancer-induced
immune tolerance have not been fully identiﬁed, available data
deﬁne multiple immune responses promoting HCC progression
and thus indicate promising targets for therapy aimed at restor-
ing anti-tumor immunity. These responses include changes in the
number or function of immune cells, cytokine level and immune
receptor or ligand expression.
On a cellular level, failure of HCC-associated antigen pre-
sentation by APCs as a consequence of decreased expression of
HLA class-I molecules [39] and ineffective tumor antigen process-
ing [40], contributes to the inability of the immune system to
recognize liver cancer. Other immune responses contributing to
HCC tolerance include increases in Tregs [41,42], invariant natu-
ral killer T cells (iNKT) [43], CD14+HLA-DR/low monocytic-like
myeloid-derived suppressor cells (MDSC) [44], and tumor-associ-
ated macrophages (TAMs) [45–47], as well as diminished CD4+ T
helper cells [48]. With respect to Tregs, an increase in CD4+CD25+
Tregs within tumor inﬁltrating lymphocytes (TILs) has been
described in association with a decrease in number and function
of CD8+ T cells [41,42]. This ﬁnding suggests the use of immune
treatments aimed at Treg depletion as a possible therapeutic
strategy for restoration of anti-tumor immune responses.
Furthermore, an increase in Treg numbers either in peripheral
circulation or within TILs has been associated with decreased
OS [49,50], and thus can be further explored as an immune prog-
nostic marker in biomarker development.
Different cytokines in association with a unique innate immu-
nity signature within the tumor microenvironment have been
reported to promote the development of HCC metastases. This
poor prognostic signature includes an increase in immunosup-
pressive cytokines (IL-4, IL-5, IL-8, and IL-10) accompanied by
suppression of immune activating cytokines (IL-1, tumor necrosis
factor (TNF), and interferon gamma (IFN-c)) [51]. Furthermore,
increased IL-10 levels in patients with advanced HCC have been
associated with shorter OS and immune dysfunction, such as
diminished activity of lymphokine-activated killer (LAK) and
natural killer (NK) cells [52].
On a receptor and ligand level, HCC immune tolerance is
mediated by immunosuppression via decreased co-stimulatory
or increased inhibitory checkpoint signaling. With respect to
co-stimulatory molecules, signiﬁcant reductions of B7-1 and
B7-2 (immune co-stimulatory ligands) expression have been
identiﬁed on HCC cells [53,54] resulting in a decrease of1422 Journal of Hepatology 2015B7/CD28 mediated activation of effector T cells. Furthermore,
several other immune co-stimulatory molecules such as CD244
(2B4) [55], CD28 [56], CD40 [57], CD137 (4-1BB) [58], and
OX-40 [58] have been studied in liver cancer and will serve as
targets for immune agonist antibodies in further clinical
development.
Immune inhibitory receptors and ligands also play a major
role in induction and maintenance of HCC immune tolerance
[35,59–66]. Several inhibitory checkpoints have been associated
with immune dysfunction in HCC including CTLA-4 [62–64],
PD-1 and its ligand (PD-L1) [35,59,61], lymphocyte-activation
gene 3 (LAG-3) [65], Tim-3 and its ligand (galectin-9) [66], and
adenosine A2a receptor (A2aR) [67]. In HCC patients, high
CTLA-4 expression on Tregs in peripheral blood has been reported
in association with a decrease in cytolytic granzyme B production
by CD8+ T cells [63]. In addition, CTLA-4 expression on CD14+DCs
was associated with IL-10 and indoleamine-2,3-dioxygenase
(IDO)-mediated inhibition of T cell proliferation and induction
of T cell apoptosis [62].
Another mechanism of tumor-induced immune tolerance is
mediated by changes in the PD-L1/PD-1 immune checkpoint
pathway. The increased expression of PD-1 has been reported
on CD8+ T cells in patients with HCC [35,59], as well as an
increase in tumor inﬁltrating and circulating PD-1+CD8+ T cells
associated with disease progression after curative hepatic resec-
tion [35]. In addition to the upregulation of PD-1 on T cells, its
ligand, PD-L1, is highly expressed on peritumoral stroma cells
(Kupffer cells, LSECs, and monocytes) as well as cancer cells, pro-
moting a PD-L1/PD-1 pathway-driven inhibition of anti-tumor T
cell responses [59,61,68,69]. This new understanding of increased
PD-1/PD-L1 expression provides the rationale for the use of PD-1
and PD-L1 immune checkpoint blocking antibodies in HCC
treatment.
However, because HCC-induced immune tolerance in the set-
ting of a tolerogenic liver environment and chronic inﬂammation
is associated with multiple immunosuppressive mechanisms,
dual or triple combinations of immune targeting agents along
with inhibitory checkpoint blockage as a backbone of therapy
are the most promising strategies for clinical development.
Spontaneous tumor-speciﬁc immune responses
Despite multiple immunosuppressive alterations, the majority of
liver cancer patients mount detectable adaptive immune
responses against tumor antigens [64,70]. The detected TAAs
against which HCC-speciﬁc CD8+ T cells have been identiﬁed
include alpha-fetoprotein (AFP) [70,71], highly immunogenic
cancer-testis antigen NY-ESO-136 [72–74], other cancer-testis
antigens such as synovial sarcoma X breakpoint 2 (SSX-2)
[72,73], catalytic enzyme telomerase reverse transcriptase
(TERT) [64,75], cyclophilin B40 [64], melanoma antigen gene-A
(MAGE-A) [72], and fetal oncoprotein glypican-3 (GPC3)
[76,77]. Generally, in vitro antigen-speciﬁc stimulation is
required to detect these T cells indicating that T cells only exist
at very low frequencies. As a promising treatment strategy,
enhancement of TAA-directed immune responses by vaccines
and immune checkpoint combinations may result in HCC growth
control and tumor regression. In addition to immune responses
against classical TAAs, spontaneous immune responses against
neo-antigens which are speciﬁc for individual tumors and impor-
tant for immunotherapy have been identiﬁed in patients withvol. 62 j 1420–1429
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Fig. 3. Immune status of an HCC-bearing host is characterized by different immune responses leading to immunity or immune tolerance and thereby promoting
tumor cell death or growth, respectively. Unfortunately, multiple immune alterations associated with carcinogenesis and disease progression shift the immune response
towards tumor immune tolerance and disease progression. Treatment approaches such as immune checkpoint blockers can bring the balance back towards immunity and
cancer cell death.
JOURNAL OF HEPATOLOGYmelanoma [78,79]. In future, the identiﬁcation of tumor-speciﬁc
mutated epitopes inducing immune responses in patients with
HCC might provide additional targets for immunotherapy.
Other immune responses, which can serve as targets for
enhancement by immunotherapy, include an increase in TILs
and cytotoxic NKs. The presence of CD4+ and CD8+ TILs has been
associated with a decrease in HCC recurrence after liver trans-
plantation or hepatic resection [43,80]. In addition, after hepatic
resection or radiofrequency ablation (RFA), the detection of cyto-
toxic (CD56dim) or activating killer immunoglobulin-like receptor
(KIR2DS5) NK cell phenotypes has been correlated with improved
OS [81]. Therefore, therapies aimed at increasing TILs or cytotoxic
NK cells could improve outcomes after potentially curative
surgery.
Collectively, all of these facts suggest that an HCC-bearing
host harbors multiple immune regulatory changes that support
tumor tolerance and disease progression rather than anti-tumor
immunity and cancer elimination. The identiﬁcation of immune
responses that affect the equilibrium between primary liver can-
cer progression and tumor elimination provides the targets for
HCC immunotherapy development (Fig. 3).Clinical trials
Multiple immune targeted therapeutic strategies aimed at induc-
ing or enhancing anti-tumor immunity against HCC have been
evaluated in clinical trials. Most of the agents have been investi-
gated as single agent therapies and are in early phases of clinical
trial development (Table 1).
Vaccines
For more than a decade, vaccines targeting HCC TAAs have been
investigated in early clinical trials with a mixed history of success
and failure [82,71,83–85]. Approximately two thirds of patientsJournal of Hepatology 2015with HCC have been reported to have detectable immune
responses to one or more TAAs [64]. These ﬁndings support vac-
cine treatments as an attractive strategy for therapeutic develop-
ment. AFP was the ﬁrst TAA to be targeted in clinic for HCC
treatment. AFP is a self-antigen normally present in fetal devel-
opment, therefore AFP is well-tolerated by the host immune sys-
tem. Different modalities have been used to overcome AFP
immune tolerance and induce immune responses in clinical vac-
cination settings. In 2003, the ﬁrst HCC vaccine clinical trial
reported detectable T cell responses to AFP after HLA-A⁄0201
patients with AFP-positive HCC were immunized with a vaccine
to four HLA-A⁄0201-restricted AFP peptides [71]. Subsequently,
a phase I/II clinical trial was completed with only transient
immunologic responses detected, possibly due to the limited
number of antigens used or deﬁcient CD4+ helper T cell support
[71]. In an attempt to overcome these limitations, a phase II clini-
cal trial used DCs pulsed with lysates of a hepatoblastoma cell
line containing multiple antigens. Of 25 patients receiving 3 or
more DC infusions, disease control rate was 28% (1 partial
response, 6 stable disease) and disease stabilization time 6–
16 months. However, a short median survival of only 168 days
was reported. Notably, detectable antigen-speciﬁc T cell immune
responses were associated with clinical responses and a fall in
AFP expression [85]. Better clinical outcomes were observed in
another HCC vaccine trial, whereby DCs pulsed with autologous
tumor lysates were administered in two different treatment
strategies: 5 courses of DCs weekly or 5 induction treatments fol-
lowed by monthly boost vaccination maintenance. Reported out-
comes among 31 treated patients were: 12.9% partial response,
54.8% stable disease and overall 1 year survival rate of 10.7%
(±9.4) vs. 63.3% (±12.0) favoring the maintenance treatment
schedule [82]. A cell-free vaccine platform was tested in the adju-
vant settings when two patients were vaccinated with plasmid
DNA followed by AFP-expressing replication-deﬁcient adenovirus
injection. AFP-speciﬁc T cell responses were observed [86], but
further studies are clearly needed to verify the clinical efﬁcacyvol. 62 j 1420–1429 1423
Table 1. Clinical trials of immune targeted therapies in hepatocellular carcinoma.
Author, year Regimen Disease 
status
Design Total number of 
patients
Results (patients) 
Immune checkpoint inhibitors 
Sangro [106], 2013 Tremelimumab  
(Anti-CTLA-4)
Advanced Single arm 21 N17: PR (3) 17.6 %, SD (10) 
58,8%; OS (21) 8.2 ms
Sangro [108], 2013 Nivolumab (Anti-PD-1) Advanced Single arm n.a. n.a.
Duffy [107], 2014 Tremelimumab + TACE 
or RFA
Advanced Single arm n.a. n.a.
HCC vaccines
Butterfield [71], 2003 4 AFP peptides Advanced Single arm 6 AFP-specific T-cell responses 
detected
Lee [82], 2005 DCs + auto-tumor lysate Advanced Single arm, 
2 schedules
14 QW×5
17 QW×5 + QM
PR (4) 12.9%, SD (17) 54.8%
1-yr OS  40.1 ms
Butterfield [118], 2006 DCs + 4 AFP peptides Advanced Single arm 16, 10 treated No objective responses
Palmer [85], 2009 DCs + HepG2 lysate Advanced Single arm 35 N25 ≥3 DCs: PR (1) 4%, SD (6) 
24%, OS (N35) 168 ds
Greten [84], 2010 GV1001 + GM-CSF Advanced Single arm 40 SD (17) 45.9%, OS 358 ds
Sawada [87], 2012 GPC3 peptides Advanced Single arm 33 PR (1) 3%, SD (19) 57.6%
OS 12.2 (G3-CTL ≥50) vs. 8.5 ms 
(G3-CTL <50)
Butterfield [86], 2014 AFP DNA prime + AdV Adjuvant Safety 2 AFP-specific T-cell responses 
detected
Adoptive cell transfer
Takayama [92], 2000 Activated T cells Adjuvant Randomized 150 RFS 37 vs. 22 % p = 0.01, 
3, 5-yr OS-no difference 
Hui [119], 2009 Activated T cells Adjuvant Randomized 127, 3 groups 1, 3,5 -yr OS-no difference
Shimizu [94], 2014 Activated T cells + DCs 
vaccine
Adjuvant Non-
randomized
94, 2 groups RFS 24.5 vs. 12.6 ms p = 0.01
OS  97.7 vs. 41.0 ms p = 0.029
Cytokines
Llovet [96], 2000 IFN-α2b Advanced Randomized 58 PR (2) 6.6%
1, 2-yr OS-no difference
Shiratori [97], 2003 IFN-α Adjuvant Randomized 74 First RR-no difference
5 yr OS 68% vs. 48%
Mazzaferro [98], 2006 IFN-α Adjuvant Randomized 150 RFS-no difference
Sun [99], 2006 IFN-α Adjuvant Randomized 236 OS 63.8 vs. 38.8 ms p = 0.0003
Lo [100], 2007 IFN-α2b Adjuvant Randomized 80 OS-trend for benefit
Chen [101], 2012 IFN-α2b Adjuvant Randomized 268 OS, RFS-no difference
Ishikawa [102], 2012 IFN-α2b/RBV Adjuvant Randomized 54 3-yr OS 90.2 vs. 61.2%
Sangro [103], 2004 Ad.IL-12 Advanced, 
GI tumors
Single arm 21 Primary liver cancer N9: 1 PR
Mazzolini [104], 2005 DCs transfected with 
Ad.IL-12
Advanced,
GI tumors
Single arm 17 Primary liver cancer N9: no 
responses
Sandrine [105], 2014 LY2157299  
(TβRI inhibitor)
Advanced Randomized 
to 2 doses
109 OS 36 ws
Others
Safran [109], 2013 Lenalidomide Advanced Single arm 40 PR (6) 15%, OS 7.6 ms
Stemmer [67], 2013 CF102 (A(3)AR agonist) Advanced Single arm 18 SD (4) 22%, OS 7.8 ms
Yen [110], 2014 GC33 (anti-glypican 3) Advanced Randomized 185 PFS, OS-no difference
 
IFN-interferon (randomized clinical trials with more than 50 patients enrolled), RBV-ribavirin, Ad.IL-12-adenoviral vector encoding human interleukin-12 genes, GI-
gastrointestinal, TbRI inhibitor-transforming growth factor-b receptor I inhibitor, TACE-transarterial chemoembolization, RFA-radiofrequency ablation, AdV-AFP-expressing
replication-deﬁcient adenovirus, A(3)AR agonist-A3 adenosine receptor agonist, RR-recurrence rate, RFS-recurrence free survival, PR-partial response, SD stable disease, OS-
overall survival, ds-days, ws-weeks, ms-months, yr-year, QW-every week, QM-every month, no difference no statistically signiﬁcant difference, N/A-not available, G3-CTL-
glypican-3-specifc cytotoxic T lymphocytes.
Reviewof this approach. Lastly, telomerase reverse transcriptase peptide
vaccines were tested in patients with advanced HCC. In a phase II
trial of GV1001, the immunomodulatory effects of low-dose
cyclophosphamide and GM-CSF were used for immune sensitiza-
tion. In 40 patients treated with this combination, no radiological1424 Journal of Hepatology 2015responses or detectable GV1001-speciﬁc immune responses were
reported, although an immune response such as a decrease in the
number of CD4+CD25+Foxp3+ Tregs was detected [84]. In another
trial HLA-A⁄24:02-restricted GPC3298–306 or HLA-A⁄02:01-
restricted GPC3144–152 peptides were tested and demonstrated avol. 62 j 1420–1429
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promising outcome: detectable GPC3-speciﬁc CTL response in 30
out of 33 patients and a positive correlation of GPC3-speciﬁc CTL
with survival [87].
These results showed the potential of HCC vaccines to elicit
immunological and clinical anti-tumor responses. New and
emerging preclinical and clinical evidence can guide the design
of effective treatment strategies with the aim of augmenting these
responses and translating the serologic anti-tumor immune
activation seen into signiﬁcant clinical beneﬁt. In the recent study,
detection of T cell responses against multiple TAA was associated
with superior tumor growth control [88]. Therefore, the develop-
ment ofmulti-antigen vaccinesmay have the potential to improve
the modest clinical efﬁcacy of vaccination observed in clinical tri-
als evaluating single-antigen vaccines. Importantly, the B7-CD28/
CLTA-4 immune checkpoint pathway was described as inhibiting
CD4+ T cell proliferation induced by DCs in response to a speciﬁc
antigen [89]. Furthermore, B7-CD28/CTLA-4 ligation increases IL-
10 production by DCs [89], which is the inhibitory cytokine cap-
able of strongly downregulating the antigen presenting function
of human monocytes [90]. These antigen-masking capacities of
immune checkpoints provide a preclinical rational for vaccine
and immune checkpoint inhibitor combinations to achieve
enhanced TAA-speciﬁc immune activation. Among other future
strategies, computer-guided HCC epitope-optimization [91],
which increases immunogenicity of known TAAs by biomedical
engineering, can be used to enhance anti-tumor immune
responses. To further maximize clinical beneﬁt, epitope-opti-
mized vaccines can be combined with immune checkpoints tar-
geting antibodies. These combinations have the potential to
achieve a synergistic immunostimulatory effect thereby providing
more meaningful clinical beneﬁts of vaccine therapies.
Adoptive cell transfer
Adoptive cell transfer (ACT) is an autologous infusion of ex-vivo
selected, activated and expanded TILs, which are extracted from
patient’s tumor or from peripheral blood. ACT has been investi-
gated in adjuvant settings for HCC treatment. In a randomized
clinical trial, 76 out of 150 patients who had undergone curative
resection received adjuvant activated autologous lymphocyte
infusions. The untreated cohort of 74 patients was considered
as the control group. Although an improvement in recurrence-
free outcomes was observed, no signiﬁcant difference in OS was
reported between treated and control groups [92]. Different
strategies have been applied to augment ACT treatment clinical
beneﬁts such as systemic administration of cytokines [93] or vac-
cination [94]. In a recently published clinical trial, patients with
HCC after curative resection were treated with an autologous
tumor lysate-pulsed DC vaccine and activated T cell transfer
(ATVAC) combination. Patient outcomes after surgery alone (52
patients) were compared with combination treatment (42
patients) and an impressive difference was reported in OS,
41.0 months vs. 97.7 months, respectively [94]. This signiﬁcant
clinical beneﬁt provided by a dual immunotherapy combination
supports a combined modality approach in the development of
new adaptive immunity targeted therapies.
Cytokines
Innate immunity treatments with cytokines have been exten-
sively studied for treatment of HCC. Interferon (IFN), which isJournal of Hepatology 2015used in the treatment of hepatitis C, was a logical choice for
HCC treatment development for its possible dual antiviral and
anti-tumor action. Multiple randomized clinical trials of different
schedules and classes of IFN have been completed with mixed
results reported with regard to recurrence-free and survival out-
comes [95–102]. Although IFN treatment has the potential to
beneﬁt selected patients with HCC, it comes at the expense of a
poor side effect proﬁle such as ﬂu-like symptoms (chills, fever,
headache, myalgia, malaise), myelosuppression, depression, and
hepatotoxicity. One possibility to overcome these effects may
be an intratumoral application, which has been achieved using
an adenovirus-based approach or transduced dendritic cells
[103,104].
Among new promising cytokine targeting approaches, a novel
small molecule inhibitor of TGF-b receptor I, LY2157299, is under
active investigation for HCC. Preliminary results of LY2157299
therapy were reported in a phase II clinical trial, where 109 were
enrolled and a median OS of 36 weeks (93.1 weeks in AFP respon-
ders vs. 29.6 weeks in non-AFP responders) was observed [105].
Currently, LY2157299 is being evaluated in a phase II, non-ran-
domized trial as a single agent or in combination with sorafenib
(NCT01246986).
Immune checkpoint inhibitors
To date, all immune checkpoint targeted therapies consist of
monoclonal antibodies developed for a speciﬁc immune target.
Although several immune checkpoint blocking agents were
described in preclinical models, the majority of clinically devel-
oped therapies are antibodies that target PD-1, PD-L1 and
CTLA-4 molecules. Among those, ipilimumab (anti-CTLA-4) in
2011 as well as pembrolizumab and nivolumab (anti-PD-1) in
2014 were approved by the FDA for the treatment of melanoma.
Among CTLA-4 targeted therapies, only tremelimumab, a fully
human IgG2 monoclonal antibody, has been clinically evaluated
in HCC. A phase II, non-controlled, multicenter tremelimumab
clinical trial enrolled patients with HCC and chronic HCV who
were not eligible for surgery or locoregional therapy. In this trial,
21 patients with advanced HCC and Child-Pugh scores A (57.1%)
or B (42.9%) were enrolled. Each treated patient received 15 mg/
kg tremelimumab every 90 days as a single agent therapy. The
trial showed a partial response rate of 17.6%, disease control rate
of 76.4% and median OS of 8.2 months. Although 45% of patients
experienced above grade 3 transaminase toxicity, the transamini-
tis was transient, only being observed with the ﬁrst tremelimu-
mab dose and without the need for systemic steroids. Notably,
tremelimumab induced a progressive decrease in viral load in
most of the patients and a complete viral response in 3 patients
[106]. These results indicate a dual effect of anti-tumor and
antiviral activity of tremelimumab, suggesting that immune
checkpoint treatment can be particularly beneﬁcial in patients
with a viral etiology such as HBV or HCV-related HCC.
Currently, we are testing tremelimumab in combination with
local therapies (TACE or RFA) in a pilot phase I/II clinical trial
[107].
Among PD-1/PD-L1 targeted treatments, nivolumab (BMS-
936558), which is a fully human IgG4 monoclonal antibody tar-
geting PD-1 receptor, is under active investigation in a phase I
dose escalation clinical trial [108]. This trial was designed to
evaluate safety and preliminary activity of nivolumab in patients
with HCC with or without HBV or HCV infection [108].vol. 62 j 1420–1429 1425
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Additionally, another anti-PD-1 monoclonal antibody pidilizu-
mab (CT-011) was evaluated in phase I clinical trial
(NCT00966251). Unfortunately, the trial was terminated early
because of slow accrual without reporting any collected results.
Although other immune checkpoint antibodies including LAG3,
TIM-3 and NK-inhibitory receptors were described to have
antineoplastic activity in preclinical models, their clinical efﬁcacy
in patients with HCC has not yet been reported [65,66].
Furthermore, preclinical studies of other immune modulatory
molecules such as CD244 (2B4) [55], CD137 (4-1BB) [58], and
OX-40 [58] identiﬁed another area for further clinical develop-
ment of immune agonist treatments.
Other immune based approaches
Several other immune targeted agents have been evaluated in
phase I/II clinical trials. Treatment with lenalidomide, an immune
modulator, was investigated in patients with advanced HCC. A
phase II trial testing the efﬁcacy of lenalidomide after sorafenib
failure reported a partial response of 15% and OS 7.6 months in
patients with advanced HCC [109]. Another phase II trial evalu-
ated the efﬁcacy of a monoclonal antibody against glypican 3,
which is an oncofetal protein expressed in liver cancer cells. In
this trial, patients with advanced HCC were randomized in a
2:1 ratio to anti-glypican antibody (GC33) vs. placebo. A total of
185 patients were treated with no difference in progression free
survival or OS observed between the two groups. Notably, analy-
sis of drug exposure revealed that high GC33 exposure had a
favorable OS relative to placebo, 9.7 vs. 6.7. Therefore, the
investigators concluded that a suboptimal dose of GC33 was
potentially responsible for the lack of treatment beneﬁt [110].
In addition, safety data has been reported for several immune tar-
geted therapies in HCC treatment, namely mapatumumab, an
agonist to tumor necrosis factor-related apoptosis-inducing
ligand receptor 1 (TRAIL-R1) [111], tigatuzumab (CS-1008), a
death receptor 5 agonist [112], and CF102, an A(3) adenosine
receptor agonist [67]. These early investigations reported good
tolerability justifying their further development.Future perspectives: biomarkers, combinations and outcome
assessment
Novel opportunities have opened for HCC therapy development
after the reported signiﬁcant clinical beneﬁts of immune check-
point blockade not only in traditionally highly immunogenic can-
cers such as melanoma, but also in other solid tumors. As part of
effective HCC immune therapeutic strategies, biomarker identiﬁ-
cation, combination of immune checkpoint targeting treatment
with known or new immune modulating therapies, and an effec-
tive outcome assessment criteria warrant further investigations.
Detection of biomarkers to guide treatment selection can
improve patient care by predicting potential responders to par-
ticular immunotherapies. The use of biomarkers offers a promise
of personalized immune treatment combinations by deﬁning
which immune pathway is the driver in each particular patient
and, thus, by identifying the optimal therapeutic target.
However, the dynamic expression and heterogeneous geographic
distribution of immune molecules present challenges for biomar-
ker development. These characteristics can lead to errors in
patient selection if patients are excluded from potentially1426 Journal of Hepatology 2015beneﬁcial treatments based on immune receptors or ligand pres-
ence in a speciﬁc time and place. Therefore, the identiﬁcation of
immune molecules which are more static in expression or use
alterations in speciﬁc immune components such as immunomod-
ulatory cytokines (IL-4, IL-10, TGF-b), immunomodulatory cells
(TILs, circulating Treg, TAA-speciﬁc CD8+ effector T cells) as sur-
rogate biomarkers could be crucial in successful immune biomar-
ker development.
Although immune-directed treatments such as cytokines, vac-
cines, and activated immune cell infusions have been investi-
gated for HCC treatment, low clinical responses were reported
after single immune agent therapy, most likely because multiple
immune pathways are involved in HCC progression in the setting
of an immune tolerogenic liver microenvironment. Typically,
HCC-bearing host immune status is characterized by mainte-
nance of tumor immune tolerance in a setting of chronic inﬂam-
mation with a major input from several immune inhibitory
checkpoints (PD-1, PD-L1, CTLA-4, LAG-3, and TIM-3)
[35,59,61,62,65,66,68]. In addition, physiologic liver immune tol-
erance to antigens, which among other immune alternations is
characterized by the upregulation of immune checkpoints, plays
a contributory role in HCC progression and resistance to
immunotherapy.
To overcome these dual liver and tumor immune tolerance
phenomena, the use of combination immunotherapies with inhi-
bitory checkpoint blockage offers the greatest promise. Immune
checkpoint pathway-targeting agents combined with the pre-
viously investigated immune therapies may provide an addi-
tional boost to immune system activation and give a ‘‘second
chance’’ to already known immune targeted treatments.
Furthermore, the development of immunotherapy in adjuvant
settings, i.e. after TACE procedure, can augment conventional
treatment beneﬁts. Additionally, double or triple immune check-
point combinations with new immune targets can be used for
anti-tumor immune response induction or enhancement. In
future investigations, simultaneous treatments with most clini-
cally developed immune checkpoint targeting therapies (anti-
CTLA-4, anti-PD-1, and anti-PD-L1 antibodies), or combinations
of checkpoint blockage with antibodies to co-stimulatory (CD-
137, OX-40) or co-inhibitory signals (TIM-3, LAG-3, NK-inhibitory
receptors), new epitope-optimized vaccines [91], or novel cyto-
kine therapies [113] are potential strategies for successful treat-
ment development. Another strategy to potentiate immune
responses is the combination of immunostimulatory drugs with
RFA. This rationale is supported by data showing RFA-induced
increase in TAAs-speciﬁc T cell responses [114]. In contrast to
RFA, combining immunotherapy with sorafenib is complicated
by the notion that sorafenib has been associated with immuno-
suppressive effects such as inhibition of NK function [115],
increase in MDCS [116], intratumoral accumulation of Tregs
and M2-types macrophages, and upregulation of PD-L1 expres-
sion [117].
Finally, a unique feature of the immune tumor response that
brings additional challenges in immune treatment development
is the potential to induce a local immune inﬂammatory reaction.
This reaction can appear as an initial increase in size or enhance-
ment of HCC lesions on magnetic resonance imaging or computed
tomography before tumor size regression or resolution of
enhancement. This phenomenon dictates usage of the Immune-
Related Response Criteria (irRC), which is a criteria based on
the total tumor volume changes and conﬁrmatory imaging atvol. 62 j 1420–1429
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least 4 weeks apart prior to declaring disease progression. To fur-
ther improve the outcome assessment, the irRC can be used in
conjunction with HCC lesion measurements to incorporate the
tumor viability features as an additional metric for treatment
response in radiologic assessment.Financial support
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